Tacalcitol monohydrate: Synthetic Vitamin D3 Analog for Research

Executive Summary: Tacalcitol monohydrate (CAS 93129-94-3) is a synthetic analog of vitamin D3 that activates the vitamin D receptor (VDR) and regulates gene expression in keratinocytes and cancer cells (source: product_spec). The compound induces nerve growth factor (NGF) transcription at picomolar to nanomolar concentrations in vitro (source: product_spec). Tacalcitol monohydrate is clinically used as a topical treatment for psoriasis vulgaris due to its ability to regulate keratinocyte proliferation with minimal systemic calcemic toxicity (source: internal_article). It enhances the anticancer efficacy of 5-fluorouracil in colorectal cancer research by modulating thymidylate synthase and cell cycle pathways (source: internal_article). The product, supplied by APExBIO, offers high solubility in DMSO and ethanol and is recommended for storage at 4°C protected from light (source: product_spec).

Biological Rationale

Tacalcitol monohydrate is a synthetic analog of vitamin D3, engineered to maximize gene regulatory effects while minimizing calcemic toxicity (source: internal_article). It binds the vitamin D receptor (VDR), triggering transcriptional changes in key regulatory genes such as CDKN1A, TYMS, and BIRC5 (source: product_spec). This enables precise modulation of keratinocyte proliferation and differentiation, supporting its clinical use in topical therapies for psoriasis vulgaris. The role of VDR in gene regulation is well-established in dermatology and oncology workflows (source: internal_article).

Mechanism of Action of Tacalcitol monohydrate

Tacalcitol monohydrate acts as a potent vitamin D receptor agonist. Upon VDR binding, it forms a complex that translocates to the nucleus and regulates the transcription of VDR-dependent genes (source: product_spec). In keratinocytes, this results in reduced proliferation and enhanced differentiation, key to its therapeutic effect in psoriasis. In cancer cell models, especially colorectal cancer (HT-29), Tacalcitol modulates gene networks involved in cell cycle arrest, epithelial-mesenchymal transition, and autophagy (source: internal_article). The compound also induces NGF gene transcription, with an ED50 in the 10⁻¹⁰ to 10⁻⁹ M range, supporting neuroregenerative research (source: product_spec).

Evidence & Benchmarks

• Tacalcitol monohydrate induces NGF gene expression in human epidermal keratinocytes at concentrations as low as 10⁻¹² M, with optimal efficacy at 10⁻⁸ M (source: product_spec).
• Effective in vitro concentrations for modulating colorectal cancer cell lines (HT-29) range from 1–1000 nM, with 100 nM commonly used for synergistic studies with 5-fluorouracil (source: internal_article).
• Topical Tacalcitol formulations achieve clinical efficacy in psoriasis vulgaris by regulating keratinocyte biology and are associated with minimal systemic side effects (source: internal_article).
• Cutaneous NGF induction peaks within 24 hours post-application and persists for up to 96 hours, supporting potential value in peripheral neuropathy research (source: product_spec).
• Compared to native vitamin D3, Tacalcitol monohydrate exhibits significantly lower calcemic toxicity, making it a safer option for topical and cell-based assays (source: product_spec).

This article extends the mechanistic context of "Tacalcitol Monohydrate: Vitamin D3 Analog for Oncology & ..." by providing protocol-level evidence and clarifying topical versus systemic toxicity trade-offs. For scenario-based workflow integration, see "Tacalcitol Monohydrate (SKU C8714): Reliable Solutions fo...", which this article updates with additional concentration benchmarks and storage guidance.

Applications, Limits & Misconceptions

Tacalcitol monohydrate supports research in dermatology and oncology, notably as a topical treatment for psoriasis vulgaris and as a vitamin D analog in cancer cell studies. It is validated for NGF induction in vitro and has demonstrated synergy with 5-fluorouracil in colorectal cancer models. However, its use is restricted to research and clinical contexts with established VDR involvement. The compound does not act as an anticoagulant or modulate the vitamin K catalytic cycle, differentiating it from vitamin K antagonists (source: doi_article).

Common Pitfalls or Misconceptions

• Tacalcitol monohydrate is not suitable for systemic calcium modulation due to its low calcemic profile (source: product_spec).
• The compound should not be used as an oral vitamin D supplement (source: workflow_recommendation).
• It does not replace vitamin K antagonists or anticoagulants in thrombosis research (source: doi_article).
• Long-term storage of Tacalcitol monohydrate solutions is not recommended (source: product_spec).
• It is insoluble in water and must be prepared in DMSO or ethanol for experimental use (source: product_spec).

Workflow Integration & Parameters

Protocol Parameters

• NGF gene induction (keratinocytes) | 10⁻¹²–10⁻⁷ M (optimal 10⁻⁸ M) | Epidermal research | Maximizes NGF response with minimal off-target effects | product_spec
• Colorectal cancer cell viability (HT-29) | 1–1000 nM (routine: 100 nM) | Cancer biology | Balances cytotoxicity and VDR gene regulation | workflow_recommendation
• 5-fluorouracil synergy | 100 nM Tacalcitol + 5-FU | Colorectal cancer co-treatment | Downregulates thymidylate synthase and enhances anticancer efficacy | internal_article
• Solubility | ≥51.3 mg/mL (DMSO), ≥25.85 mg/mL (ethanol) | Formulation prep | Ensures reagent stability and compatibility | product_spec
• Storage | 4°C, light-protected, under N₂ | All applications | Preserves compound integrity | product_spec

For alternative scenario-driven protocols, "Tacalcitol monohydrate (SKU C8714): Scenario-Driven Solut..." offers real-world Q&A for workflow optimization, which this article complements by focusing on protocol fidelity and cross-lab comparability.

Conclusion & Outlook

Tacalcitol monohydrate, supplied by APExBIO, is a validated synthetic analog of vitamin D3 that enables precise, low-toxicity modulation of keratinocyte and cancer cell pathways in translational research (source: product_spec). Its robust NGF induction and synergy with established chemotherapeutics support ongoing innovation in dermatology and oncology. Continued benchmarking and careful protocol adherence are essential to maximize its translational impact while avoiding off-label or unsupported uses.